Related Experiment Video
Updated: May 7, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Changes of liver fat content and transaminases in obese children after 12-mo nutritional intervention
Elvira Verduci1, Carlo Pozzato, Giuseppe Banderali
1Elvira Verduci, Giuseppe Banderali, Giovanni Radaelli, Chiara Arrizza, Enrica Riva, Marcello Giovannini, Department of Pediatrics, San Paolo Hospital, University of Milan, 20142 Milan, Italy.
Insights
Nutritional intervention in obese children reduced liver fat content and improved liver enzymes. Changes in liver fat fraction (FF) correlated with changes in aspartate aminotransferase (AST) and alanine aminotransferase (ALT), suggesting a new monitoring approach for fatty liver disease.
Area of Science:
- Pediatric Endocrinology
- Hepatology
- Radiology
- Nutritional Science
Background:
- Childhood obesity is a growing concern, often associated with nonalcoholic fatty liver disease (NAFLD).
- Accurate monitoring of liver fat content and its biochemical markers is crucial for assessing intervention effectiveness in obese children.
Purpose of the Study:
- To investigate the relationship between changes in liver fat content and biochemical parameters in obese children following a 1-year nutritional intervention.
- To explore the potential of magnetic resonance imaging (MRI) in monitoring NAFLD progression and treatment response in pediatric populations.
Main Methods:
- Forty-six obese children (aged 6-14 years) underwent baseline and 1-year follow-up assessments.
- Assessments included body mass index (BMI) Z-scores, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, liver ultrasonography (US), and chemical-shift MRI to determine liver fat fraction (FF).
- A nutritional-behavioral intervention focused on a balanced diet and active lifestyle was implemented.
Main Results:
- The intervention led to significant reductions in energy, fat, carbohydrate, and protein intake.
- Prevalence of elevated liver fat fraction (FF ≥ 9%) decreased from 34.8% to 8.7% (P < 0.01), with a mean reduction of 7.8%.
- Changes in liver fat fraction (FF) were significantly associated with changes in AST (P = 0.027) and ALT (P = 0.024). FF change was independently associated with AST change (adjusted regression coefficient 0.348, P = 0.048).
Conclusions:
- Longitudinal changes in liver fat content, measured by MRI, are associated with changes in serum transaminases in obese children.
- These findings suggest that MRI-based liver fat assessment, combined with biochemical markers, may offer a novel approach for monitoring NAFLD in pediatric obesity.
Aim:
To assess a relationship between longitudinal changes in liver fat content and biochemical parameters in obese children after 1-year nutritional intervention.
Methods:
Forty-six obese children, 21 males and 25 females, aged 6-14 years, underwent metabolic measurements, liver ultrasonography (US) and chemical-shift magnetic resonance imaging (MRI) examinations at baseline and after 1-year nutritional intervention. A child was defined obese if her/his body mass index (BMI) was above the age- and sex-adjusted BMI Cole's curve passing through the cut-off of 30 kg/m(2) at 18 years. BMI Z scores were calculated and adjusted for age and gender by using the Cole's LMS-method and Italian reference data. Biochemistry included serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Abdominal US and chemical-shift MRI were performed according to a randomized sequence. The same radiologist performed US by a GE Logiq 9 (General Electric Healthcare Medical Systems, Milwaukee, WI, United States) using a 3.5-MHz convex array transducer. Liver echogenicity was evaluated independently on videotape by 3 radiologists unaware of the child and MRI outcomes, and a consensus was established. Another experienced radiologist, unaware of the child and US data, performed the abdominal chemical-shift MRI with a 1-t system NT-Intera (Philips Medical Systems, Best, The Netherlands) and a phased-array coil. Liver fat fraction (FF) on MRI was judged elevated when greater than 9%. A FF > 18% was considered expressing more severe cases of fatty liver according to Fishbein. A nutritional-behavioral intervention was recommended to promote a normocaloric balanced diet and active lifestyle based on the Italian guidelines for treatment of childhood obesity.
Results:
Compared to baseline, at the end of intervention children showed lower intakes of energy (mean ± SD: 2549 ± 1238 Kcal vs 1770 ± 622 Kcal, P < 0.0001), total fat (90 ± 47 g vs 52 ± 23 g, P < 0.0001), carbohydrates (356 ± 174 g vs 241 ± 111 g, P = 0.001), and protein (99 ± 48 g vs 75 ± 23 g, P = 0.006) intakes. Prevalence of FF ≥ 9% declined from 34.8% to 8.7% (P < 0.01), with a mean reduction of 7.8% (95%CI: 5.0-10.6). At baseline, FF was associated with liver biochemical parameters (maximum P < 0.001). At the end of the intervention association was found with AST (P = 0.017). Change of FF was associated with change in AST (P = 0.027) and ALT (P = 0.024). Rate of increased liver echogenicity declined from 45.6% to 21.7% (P < 0.0001). Liver echogenicity was associated with ALT at baseline only (P < 0.001). An age- and sex- adjusted multiple regression analysis showed that FF change was independently associated with change in serum AST (adjusted regression coefficient 0.348, P = 0.048).
Conclusion:
The results suggest that in obese children longitudinal changes in liver fat content based on MRI may be associated with change in serum transaminases suggesting novelty in monitoring nonalcoholic fatty liver disease.
More Related Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
07:13Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH
Published on: April 20, 2021
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test